22nd November, 2006.

Eastland Medical Systems LTD

The Manager,
Company Announcement Platform,
Australian Stock Exchange,
20 Bridge Street,
Sydney. N.S.W. 2000

By E-Lodgement of 5 pages.

ASX ANNOUNCEMENT
GENERAL MEETING

Eastland Medical Systems Ltd held its Annual General Meeting on 22 November 2006 at 2.30 p.m. WST this afternoon. The Resolutions contained in the Notice of Meeting, with the exception of Resolution 2.3, were dealt with and passed by shareholders and, in accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act, the Company wishes to advise the following:

Resolution **1: Ordinary Resolution:**
Non-binding advisory vote on the Remuneration Report. "That the Remuneration Report as set out in the Annual Report for the financial year ended 30 June 2006, be adopted."

was passed by a show of hands.

The total number of proxy votes in respect of this Resolution specified that:

(i) The proxy is to vote for the resolution	(number of shares)	(34,259,793)
(ii) Chairman's proxy with intent not stated – the Chairman voted in favour of the resolution	(number of shares)	(1,263,965)
(iii) The proxy is to vote against the resolution	(number of shares)	(282,627)
(iv) The proxy is to vote at the Proxy's discretion	(number of shares)	(Nil)
(v) The proxy is to abstain on the resolution	(number of shares)	(103,722)

Resolution **2.1: Ordinary Resolution:**
"To re-elect Mr. Francis (Don) O'Sullivan, retiring by rotation in accordance with clause 3.6 (b) of the Company's Constitution, and being eligible offers himself for re-election"

was passed by a show of hands.

The total number of proxy votes in respect of this Resolution specified that:

(i) The proxy is to vote for the resolution	(number of shares)	(33,392,265)
(ii) Chairman's proxy with intent not stated – the Chairman voted in favour of the resolution	(number of shares)	(1,263,965)
(iii) The proxy is to vote against the resolution	(number of shares)	(1,193,627)
(iv) The proxy is to vote at the Proxy's discretion	(number of shares)	(Nil)
(v) The proxy is to abstain on the resolution	(number of shares)	(60,250)

Resolution **2.2: Ordinary Resolution:**
"To re-elect Mr. Peter Jooste QC, who was appointed by the Board after the last Annual General Meeting, retiring in accordance with clause 3.3 (a) "Appointment by the Board" of the Company's Constitution, and being eligible offers himself for re-election"

was passed by a show of hands.

The total number of proxy votes in respect of this Resolution specified that:

(i) The proxy is to vote for the resolution	(number of shares)	(34,385,892)
(ii) Chairman's proxy with intent not stated – the Chairman voted in favour of the resolution	(number of shares)	(1,263,965)
(iii) The proxy is to vote against the resolution	(number of shares)	(250,250)
(iv) The proxy is to vote at the Proxy's discretion	(number of shares)	(Nil)
(v) The proxy is to abstain on the resolution	(number of shares)	(10,000)

Unit 6
680 Murray Street
West Perth
Western Australia
6005

PO Box 898
West Perth
Western Australia
6872

61 8 **9481 1844**
61 8 9486 4998

ACN 090 987 250

Resolution **2.3: Ordinary Resolution:**

"To re-elect Mr. Peter Tiede, who was appointed by the Board after the last Annual General Meeting, retiring in accordance with clause 3.3 (a) "Appointment by the Board" of the Company's Constitution, and being eligible offers himself for re-election"

Mr. Tiede advised earlier that he was not standing for re election and voting on this Resolution was not conducted. Mr. Tiede ceased to be a Director from the close of the General Meeting today.

Resolution **2.4: Ordinary Resolution:**

"To re-elect Mr. David Whitelaw, retiring by rotation in accordance with clause 3.6 (b) of the Company's Constitution, and being eligible offers himself for re-election"

was passed by a show of hands.

The total number of proxy votes in respect of this Resolution specified that:

(i) The proxy is to vote for the resolution	(number of shares)	(34,517,170)
(ii) Chairman's proxy with intent not stated – the Chairman voted in favour of the resolution	(number of shares)	(1,263,965)
(iii) The proxy is to vote against the resolution	(number of shares)	(118,972)
(iv) The proxy is to vote at the Proxy's discretion	(number of shares)	(Nil)
(v) The proxy is to abstain on the resolution	(number of shares)	(10,000)

Resolution **3.1: Ordinary Resolution:**

"That pursuant to Listing Rule 7.4 of the Listing Rules of Australian Stock Exchange Limited, and for all other purposes, shareholders ratify the allotment and issue of 2,000,000 fully paid ordinary shares issued at $0.20 cents per share, to acquire a 50% shareholding of Ampack Medical Pty Ltd."

was passed by a show of hands.

The total number of proxy votes in respect of the Resolution specified that:

(i) The proxy is to vote for the resolution		(34,562,420)
(ii) Chairman's proxy with intent not stated – the Chairman voted in favour of the Resolution	(number of shares)	(1,263,965)
(iii) The proxy is to vote against the resolution	(number of shares)	(73,722)
(iv) The proxy is to vote at the Proxy's discretion	(number of shares)	(Nil)
(v) The proxy is to abstain on the resolution	(number of shares)	(10,000)

The Company disregarded any votes cast on this Resolution by the recipient of this allotment, the remaining Ampack shareholder and any associates of those persons.

Resolution **3.2: Ordinary Resolution:**

"That pursuant to Listing Rule 7.4 of the Listing Rules of Australian Stock Exchange Limited, and for all other purposes, shareholders ratify the allotment of 178,000 Convertible Notes at $1.00 with a conversion right of seven (7) fully paid ordinary shares for each $1.00 Note and seven (7) free attaching options exercisable at $0.20 cents for each 2 x $1.00 Note at any time up until 31 August 2008."

was passed by a show of hands.

The total number of proxy votes in respect of the Resolution specified that:

(i) The proxy is to vote for the resolution		(34,512,170)
(ii) Chairman's proxy with intent not stated – the Chairman voted in favour of the Resolution	(number of shares)	(1,263,965)
(iii) The proxy is to vote against the resolution	(number of shares)	(123,972)
(iv) The proxy is to vote at the Proxy's discretion	(number of shares)	(Nil)
(v) The proxy is to abstain on the resolution	(number of shares)	(10,000)

The Company disregarded any votes cast by the recipients of the Notes and by any associates of those persons.

Resolution **3.3: Ordinary Resolution:**

"That pursuant to Listing Rule 7.4 of the Listing Rules of Australian Stock Exchange Limited, and for all other purposes, shareholders ratify the allotment and issue of 5,670,000 fully paid ordinary shares issued at $0.15 cents per share as part settlement, to acquire the Business Assets of Westcoast Surgical and Medical Supplies."

was passed by a show of hands.

The total number of proxy votes in respect of the Resolution specified that:

(i) The proxy is to vote for the resolution		(34,631,142)
(ii) Chairman's proxy with intent not stated – the Chairman voted in favour of the Resolution	(number of shares)	(1,263,965)
(iii) The proxy is to vote against the resolution	(number of shares)	(5,000)
(iv) The proxy is to vote at the Proxy's discretion	(number of shares)	(Nil)
(v) The proxy is to abstain on the resolution	(number of shares)	(10,000)

The Company disregarded any votes cast by the recipients of this allotment and by any associates of those persons.

Resolution **3.4: Ordinary Resolution:**

"That pursuant to Listing Rule 7.4 of the Listing Rules of Australian Stock Exchange Limited, and for all other purposes, shareholders ratify the allotment and issue of 500,000 ordinary unlisted options issued under the terms of the Business and Asset Sale Agreement for the acquisition of Westcoast Surgical and Medical Supplies, exercisable at $0.15 cents at any time expiring 31 August 2008."

was passed by a show of hands.

The total number of proxy votes in respect of the Resolution specified that:

(i) The proxy is to vote for the resolution		(34,631,142)
(ii) Chairman's proxy with intent not stated – the Chairman voted in favour of the Resolution	(number of shares)	(1,263,965)
(iii) The proxy is to vote against the resolution	(number of shares)	(5,000)
(iv) The proxy is to vote at the Proxy's discretion	(number of shares)	(Nil)
(v) The proxy is to abstain on the resolution	(number of shares)	(10,000)

The Company disregarded any votes cast by the recipients of this allotment and by any associates of those persons.

Resolution **3.5: Ordinary Resolution:**

"That pursuant to Listing Rule 7.4 of the Listing Rules of Australian Stock Exchange Limited, and for all other purposes, shareholders ratify the allotment of 179,133 Convertible Notes at $1.00 with a conversion right of seven (7) fully paid ordinary shares for each $1.00 Note and seven (7) free attaching options exercisable at $0.20 cents for each 2 x $1.00 Note at any time up until 31 August 2008."

was passed by a show of hands.

The total number of proxy votes in respect of the Resolution specified that:

(i) The proxy is to vote for the resolution		(34,512,170)
(ii) Chairman's proxy with intent not stated – the Chairman voted in favour of the Resolution	(number of shares)	(1,263,965)
(iii) The proxy is to vote against the resolution	(number of shares)	(123,972)
(iv) The proxy is to vote at the Proxy's discretion	(number of shares)	(Nil)
(v) The proxy is to abstain on the resolution	(number of shares)	(10,000)

The Company disregarded any votes cast by the recipients of the Notes and by any associates of those persons.

The Board advises that there was no other business lawfully raised or brought forward at the meeting.

Mr. Dermot Patterson, the Company's Chief Executive Officer provided his address to shareholders at this afternoon's meeting and we have attached a copy of this address for release.

Yours sincerely,

T Strahan

Trevor Strahan.
Company Secretary.

2006 ANNUAL GENERAL MEETING - 22 NOVEMBER 2006
EASTLAND MEDICAL SYSTEMS LIMITED

CHIEF EXECUTIVE OFFICER'S REPORT

I would like to provide you with an update on the strategy and performance following my initial review since my appointment ten weeks ago in September 2006.

The review considered the Company's current operations, performance over the last 5 months and key milestones to be achieved in this current financial year. It also focused on assessing Eastland's commercial strategies and their implementation todate. As part of the process I incorporated extensive discussions with staff, distributors, customers, investors and other stakeholders.

I have found this process to be both informative and very positive. I have been impressed by the dedication and motivation of our staff, and the sound basis and business principals for how the company has been grown.

Eastland's key strategic imperatives in driving shareholder value through becoming a leading Healthcare company are to:

- Increase sales penetration in our domestic market, where we already have a presence
- Develop a strong revenue and profit platform within Australia, from which to expand globally
- Utilise our International Medical Devices (IMD) shareholding for future growth
- Introduction of a range of safe medical devices for the international market
- Secure CE regulatory approval for our Clip-On safe needle in the important markets of the United Kingdom and Europe
- Secure TGA regulatory approval on the back of CE approval
- Secure NHS acceptance of our Clip-On for the United Kingdom market
- Increase the frequency of engagement with investors and stakeholders
- Seek further strategic partnerships and business development opportunities

In addition many advances and milestones had been achieved in the past five months including:

- Achievement of a maiden profit for FY 2006
- The acquisition of Westcoast Surgical here in Western Australia
- The acquisition of a 50% shareholding in Ampack Medical based here in Western Australia
- The supply of 4500 Clip-On samples to the United Kingdom for the CE approval process
- The supply of 200 new commercial samples to be used for the National Health Service acceptance in the United Kingdom

In addition a number of internal initiatives have now been implemented since my arrival to overcome previous operational difficulties, including:

- Actively managing our current distributors, both within Australia and in South Africa
- Introduction of direct sales representation into Victoria
- Introduction of new management at MIA
- Accelerating the running down of old inventory stock and capitalising on orders from new products.
- Continue to actively support the approval process in the UK
- Refocusing of pricing strategies to increase market penetration

The overall upside potential for Eastland remains very positive, with our planned strengthening of our domestic distribution network during Q4 FY 2007.

There are a number of key milestones that are scheduled to be achieved in the 2007 financial year. The achievement of these milestones will underpin our corporate and revenue objectives.

- Realisation of expected revenues from the enlarged distribution platform within Australia
- Continued integration of the Australian and international business operations
- Introduction of new exclusive niche product offerings into the market
- Market introduction of our Pro-R safe retractable syringe into Australia and South Africa
- Strengthening of our Eastland operational and product brands
- The incorporation of Eastland AG to provide a platform for potential joint venture partners for the PAP technology in the automotive and needle industries.
- Completion of the compliance listing for EMS SA
- Acquiring a manufacturing platform in South Africa
- Completing the CE regulatory approval in the UK and Europe

These milestones and the detailed plans for each of them needs to be implemented to achieve our objectives for FY 2007.

Some of the milestones are reliant on external-driven variables which are beyond our control. However, the milestones we have set remain achievable and I look forward to updating our shareholders on the progress of these in due course.

In conclusion, with Clip-On progressing to market entry in the UK, we will be looking to commercialise our other patented safe injectable devices as we move forward. In addition we are looking for new business opportunities globally to continue our strategy of developing a business portfolio that will offer further diversity in revenue streams.

The future outlook for Eastland remains bright. Our revenues year to date are in line with expectations and our expectation for growth is strong.

Thank you and I look forward to addressing you at our next AGM.

Dermot Patterson
Chief Executive Officer.
Eastland Medical Systems Ltd.